CML Fadi Haddad Metformin
Fadi Haddad/mdanderson.org

Fadi Haddad: Could Metformin Prevent Progression to AML?

Fadi Haddad, Assistant Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Intresting article in Nature showed that metformin led to a markedly lower prevalence of DNMT3A R822-mutant clonal hematopoiesis.

Could metofrmin prevent progression to AML?”

Title: Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis

Authors: Malgorzata Gozdecka, Monika Dudek, Sean Wen, Muxin Gu, Richard J. Stopforth, Justyna Rak, Aristi Damaskou, Guinevere L. Grice, Matthew A. McLoughlin, Laura Bond, Rachael Wilson, George Giotopoulos, Vijaya Mahalingam Shanmugiah, Rula Bany Bakar, Eliza Yankova, Jonathan L. Cooper, Nisha Narayan, Sarah J. Horton, Ryan Asby, Dean C. Pask, Annalisa Mupo, Graham Duddy, Ludovica Marando, Theodoros Georgomanolis, George S. Vassiliou

Read The Full Article at Nature.

Fadi Haddad: Could Metformin Prevent Progression to AML?

More posts featuring Fadi Haddad on OncoDaily.